Home
>
US Stocks
>
Viracta Therapeutics Inc
Viracta Therapeutics Inc
VIRX

Viracta Therapeutics Inc (VIRX)

$2.758.33%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open$2.93
Today Low/High$2.75 / $2.96
52 Week Low/High$2.87 / $24.8
Market Cap$118.28M

Company Details

Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphomas. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
OrganisationViracta Therapeutics Inc
HeadquatersSouth San Francisco, California, US
CEODayton Misfeldt

Discover more

Frequently Asked Questions

What is Viracta Therapeutics Inc (VIRX) share price today?

Can Indians buy Viracta Therapeutics Inc (VIRX) shares?

How can I buy Viracta Therapeutics Inc (VIRX) shares from India?

Can Fractional shares of Viracta Therapeutics Inc (VIRX) be purchased?

What are the documents required to start investing in Viracta Therapeutics Inc (VIRX) stocks?